PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijmmLink to Publisher's site
 
Int J Mol Med. 2016 July; 38(1): 161–171.
Published online 2016 May 12. doi:  10.3892/ijmm.2016.2586
PMCID: PMC4899006

Hypothermic machine perfusion increases A20 expression which protects renal cells against ischemia/reperfusion injury by suppressing inflammation, apoptosis and necroptosis

Abstract

There is an urgent need to improve the quality of donor organs obtained after cardiac death. In the present study, we examined the potential mechanisms through which A20 protects renal cells against ischemia/reperfusion injury (IRI) following either hypothermic machine perfusion (HMP) or static cold storage (CS) of the kidneys in a rabbit model. The expression of markers of apoptosis, necroptosis and inflammation in frozen kidney tissues were detected by western blot analysis, RT-qPCR and ELISA. Compared with the CS group, A20 expression was significantly higher in the tissue from the HMP group (P<0.01). By contrast, the expression of nuclear factor-κB (NF-κB) and tumor necrosis factor-α (TNF-α) was significantly lower in HMP group (P<0.01), whereas IκBα expression was significantly higher (P<0.01). The expression of apoptosis signal-regulating kinase 1 (ASK1), phosphorylated (p-)c-Jun N-terminal kinase (JNK) and activated caspase-3 in the HMP group was significantly downregulated compared with that in the CS group (all P<0.01). In addition, A20 inhibited receptor-interacting protein kinase 3 (RIPK3)-mediated necroptosis in the kidney. RIPK3 expression in the HMP group was significantly lower than that in the CS group (P<0.01), although the levels in both groups were higher than those in the sham group (P<0.01). Based on these findings, we propose a novel mechanism underlying the anti-apoptotic effect of A20 in renal cells in which A20 binds to ASK1 and promotes the degradation of ASK1 leading to the suppression of JNK activation and eventually, to the blockade of apoptosis. Thus, HMP reduces inflammation, apoptosis and necroptosis by upregulating the expression of A20; this mechanism may be responsible for protecting the kidney against IRI.

Keywords: apoptosis, inflammation, necroptosis, A20, hypothermia machine perfusion, kidney

Introduction

Kidney transplantation is the optimal treatment for patients with end-stage renal disease (ESRD) (1); however, a severe shortage of organs is the permanent bottleneck which limits the availability of organ transplantation as a treatment. To increase the donor pool, novel and innovative means of increasing the number of suitable kidneys for transplantation have been established, including expanded criteria donation (ECD) and donation after cardiac death (DCD). However, the organs procured from DCD donors are at greater risk of serious ischemia-reperfusion injury (IRI). IRI is known to be a risk factor for delayed graft function (DGF), rejection, renal fibrosis and both poorer short- and long-term graft function as well as reduced patient survival following transplantation (25). Thus, methods to optimize the quality of DCD kidneys and improve short-term and long-term outcomes are urgently required. Hypothermic machine perfusion (HMP) and static cold storage (CS) are methods that have been developed over the past 30 years in order to maximize the benefit of donated kidneys (6). In fact, HMP has been reported to obtain better transplantation outcomes compared with CS (710). Although this potential benefit of HMP remains poorly understood, it may provide an opportunity to improve organ quality in combination with pharmacological and gene transfer therapies (11).

Inflammation is an invariable finding in acute and chronic kidney injury (12) and is a critical initiating and aggravating factor in kidney damage (13). A pivotal mediator of this inflammatory response is the transcription factor nuclear factor-κB (NF-κB), which regulates the expression of adhesion molecules, chemokines and other pro-inflammatory molecules in renal or endothelial cells (ECs) (1416). The best-characterized signaling pathways that lead to NF-κB activation are those stimulated by members of the interleukin-1 (IL-1)/Toll-like receptor family and tumor necrosis factor-α (TNF-α) (17).

Traditionally, two forms of cell death have been identified: apoptosis (programmed cell death) and necrosis (18). However, another form of cell death, known as necroptosis, has recently been identified which has the characteristics of apoptosis and necrosis (19). Evidence suggests that apoptotic pathways contribute to renal tubular injury (20,21). Receptor-interacting protein kinase 3 (RIPK3)-mediated necroptosis in donor kidneys may promote inflammatory injury and has a major impact on renal IRI and graft survival (22).

A20, also known as tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), was originally identified as a TNF-inducible gene product of ECs (23). It has been demonstrated that A20 mRNA is markedly upregulated in the mouse kidney in response to TNF-α treatment, and A20 knockout mice are hypersensitive to the pro-inflammatory effects of TNF-α and lipopolysaccharide, which results in premature death due to severe multi-organ inflammation and cachexia (24,25). A20 is a potent anti-inflammatory protein associated with multiple human autoimmune diseases and human malignancies (26,27). A20 also enhances cell viability and has been shown to protect ECs, proximal tubular epithelial cells (TECs) and pancreatic islets from injury in response to various stimuli including TNF-α and oxidative stress (2830). A20 is a cytoplasmic zinc-finger protein that has been characterized as a dual inhibitor of NF-κB activation and cell death (31). Furthermore, A20 inhibits RIPK3-dependent necroptosis thereby attenuating inflammatory injury (32). Thus, measuring A20 at the mRNA and protein levels has the potential to be diagnostic and prognostic of transplantation outcomes and therefore may be important in determining timely therapeutic interventions in order to prolong graft survival (33). HMP is known to be superior to CS as a method of donor organ storage following cardiac death; therefore, in this study, we examined the molecular mechanism underlying the protective effects of HMP on donor organ storage.

Materials and methods

Animals

Eighteen healthy male rabbits (obtained from the Animal Experiment Center of Wuhan University/Wan Qian Jia He Experimental Animal Culture Center, Wuhan, China) weighing 3.1±0.2 kg (aged 12–13 weeks) were randomly allocated to three groups (n=6/group).

All animal experiments were performed in accordance with the Experimental Animal Regulations established by The Ministry of Science and Technology of the People's Republic of China and the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health. The study received ethics approval from the Ethics Committee of Zhongnan Hospital of Wuhan University. Prior to performing the experiments, all the animals were subjected to an overnight fast with unlimited access to water.

Establishment of the animal model

The rabbits were anesthetized and surgery was performed at the appropriate room temperature. In the sham group, the left kidney was subjected to warm ischemia for 25 min by clamping the left renal pedicle which was followed by reperfusion for 29 h. In the HMP group, the left renal pedicle was clamped for 25 min which was followed by recovered blood flow for 1 h. The kidneys were then hypothermically (4–8°C) preserved in vivo for 4 h in HCA-II solution (Shanghai Chang Zheng Hospital, Shanghai, China) using HMP (n=6) or CS (n=6). In the HMP group, the left kidneys were connected in vivo to the LifePort Kidney Transporter (Organ Recovery System, Chicago, IL, USA). A mean arterial pressure of 58±7.5 mmHg was maintained during the period of perfusion. Following anastomosis of the vessels, a right nephrectomy was performed and specimens were obtained 24 h later. All procedures were identical in both groups, with the exception that the kidneys were stored in polystyrene organ boxes (Zhejiang Zhenhua Plastic Co., Ltd., Zhejiang, China) in the CS group.

Western blot analysis of A20, apoptosis signal-regulating kinase 1 (ASK1), c-Jun N-terminal kinase (JNK), phosphorylated (p-)JNK, pro-caspase-3, cleaved caspase-3, RIPK3, mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1), NF-κB and IκBα expression

The kidney tissue was homogenized in RIPA buffer containing a protease inhibitor and then centrifuged at 15,000 × g for 20 min at 4°C in order to extract the total proteins. The supernatants were collected and the total protein concentrations were normalized using the BCA assay (Beyotime Institute of Biotechnology, Shanghai, China). The proteins were separated by 10–12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and transferred to PVDF membranes (Millipore, Billerica, MA, USA). The blots were incubated with the antibodies specific for the following: A20 (RS-92803R), ASK1 (RS-90145R), MALT1 (RS-96863R) and IκBα (RS-90167R) (Shanghai Ruiqi Bio-Technology, Inc., Shanghai, China); caspase-3 (GB13009), and JNK (GB17018)/p-JNK (GB13019-M) (Wuhan Goodbio Technology, Inc., Hubei, China); NF-κB (bs-0465R) and RIPK3 (bs-3551R) (Bioss Bio Technology, Inc., Beijing, China). β-actin or GAPDH were used as controls. Following incubation with anti-IgG, the proteins were visualized using an ECL reagent followed by exposure to X-ray film. Quantification of band density was determined using the Quantity One software package (Bio-Rad Laboratories, Hercules, CA, USA).

Reverse transcription quantitative-polymerase chain reaction (RT-qPCR)

Total RNA was extracted from tissue using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was synthesized using PrimeScript RT reagent kit with cDNA eraser (Invitrogen) according to the manufacturer's instructions. After PCR amplification, the products of A20, XIAP, GADD45β, MnSOD and c-FLIP were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. One-step real-time RT-PCR was performed using SYBR Premix Ex Taq™ (Takara, Hubei, China) in a real-time PCR machine (ABI 7900; Applied Biosystems, Carlsbad, CA, USA) according to the manufacturers' instructions. The primer pairs used are listed in Table I. GAPDH and β-actin were used as endogenous controls. The relative mRNA expression levels of each target gene were normalized to those of the controls using the 2−ΔΔCT method.

Table I
Sequences of rabbit primers used for comparative RT-qPCR.

TdT-mediated biotin-16-dUTP nick-end labeling (TUNEL) assay

Apoptotic cell death was evaluated using the One-Step TUNEL Apoptosis assay kit (Beyotime Institute of Biotechnology). Briefly, the apoptotic cells were identified by the addition of digoxigenin-deoxynucleoside triphosphate (dNTP) fragments to the 3′-OH DNA termini by TdT followed by labeling with peroxidase- or Rhodamine-linked anti-digoxigenin antibodies and visualization with either diaminobenzidine (DAB; Beyotime Institute of Biotechnology) followed by light microscopy or fluorescence microscopy (Olympus Corporation, Tokyo, Japan). As a positive control, sections were incubated with DNase I for 10 min at room temperature (25°C) prior to the fluorescent labeling procedure. The cells labeled with green fluorescence were described as apoptotic cells. The cells were labeled with 4′,6-diamidino-2-phenylindole (DAPI; Beyotime Institute of Biotechnology) for nuclear staining.

Immunohistochemical analysis of A20 and RIPK3 expression

The expression of A20 and RIPK3 in paraffin-embedded tissue sections was analyzed by immunohistochemistry (IHC). Following deparaffinization and antigen retrieval in 10 mM sodium citrate buffer (pH 6.0) using the pressure cooker method at full power for 4 min, the tissue sections were exposed to 3% H2O2 for 10 min. The tissue sections were then blocked for 30 min at room temperature with 5% bovine serum albumin (BSA). The sections were incubated with anti-A20 (1:40) and anti-RIPK3 (1:200) antibodies overnight at 4°C in a humid chamber and then incubated with the horseradish peroxidase (HRP)-conjugated secondary detection antibody for 30 min at 37°C. The sections were then incubated with DAB chromogen, counterstained with hematoxylin (Beyotime Institute of Biotechnology) and finally dehydrated, cleared and mounted with neutral gum. The sections were washed with several changes of Tris-buffered saline (TBS)-0.3% Tween buffer between each step.

Enzyme-linked immunosorbent assay (ELISA)

TNF-α levels were measured using a specific ELISA kit (Elabscience Biotechnology Co., Ltd., Hubei, China) according to the manufacturer's instructions. The homogenates were first centrifuged at 10,000 × g for 25 min in order to remove solid tissue debris and the supernatant was collected and assayed.

Measurement of reactive oxygen species (ROS) and malonaldehyde (MDA) levels

The levels of ROS and MDA are established markers used to determine the extent of tissue oxidative damage and cell viability. The kidney tissues were thawed following homogenization according to the manufacturer's instructions. (Jiancheng Technology Co., Ltd., Nanjing, China). The supernatant was assayed using the Multiskan MK3 (Thermo Fisher Scientific, Waltham, MA, USA).

Statistical analysis

The results are presented as the means ± standard deviation (SD). Statistical analysis was performed by one-way analysis of variance (ANOVA) after proving the assumption of normality (Shapiro-Wilk testing) and then followed by LSD multiple comparison tests when F was significant. The software SPSS 17.0 for Windows (SPSS, Inc., Chicago, IL, USA) was used. P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of A20, but not of other NF-κB target genes significantly increases in the HMP group compared with that in the CS group

Fig. 1A shows the results of the analysis of A20 and MALT1 expression obtained by western blot analysis and RT-qPCR in the different treatment groups. HMP treatment significantly increased A20 expression compared with that in the CS group (P<0.01). The expression of MALT1 (in the kidney), which cleaves A20 (34), in the HMP group was lower than that in the CS group (P<0.01). Fig. 1B and C show the results of RT-qPCR of A20, X-linked inhibitor of apoptosis protein (XIAP), manganese superoxide dismutase (MnSOD), growth arrest and DNA damage-inducible 45β (GADD45β) and cellular FLICE-inhibitory proteins (c-FLIP) expression in the different treatment groups. It has been proposed that a subset of NF-κB target genes, including XIAP, MnSOD, GADD45β, and c-FLIP, are capable of antagonizing JNK signaling (3537). In the present study, the expression of XIAP and GADD45β were marginally or poorly induced whereas MnSOD levels were slightly lower in both the HMP and CS groups compared with those in the sham group. Although the expression of c-FLIP was increased in both the HMP and CS groups compared with that in the sham group, there was no significant difference among the three groups. Thus, these findings clearly indicate that A20 rather than the JNK inhibitors, plays a predominant role in the suppression of JNK signaling in apoptosis.

Figure 1
(A) A20 and mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) expression in the three groups were analyzed by western blot analysis and RT-qPCR. Representative blots are shown. Western blot analysis of (a) A20 and (b) MALT1 protein. ...

Immunohistochemical analysis reveals higher A20 expression in the HMP group compared with that in the CS group

The immunohistochemical analysis of the location and levels of A20 expression in the kidneys in the HMP and CS groups is shown in Fig. 2. A20 was expressed predominantly in the TECs, with significantly more abundant expression observed in the HMP group compared with that in the CS group (P<0.01).

Figure 2
Immunohistochemical analysis of the location and levels of A20 expression in the kidneys in the hypothermic machine perfusion (HMP) and cold storage (CS) groups. The HMP group showed significantly increased expression of A20 compared with that in the ...

Extent of kidney injury significantly decreases in the HMP group compared with that in the CS group

Renal cellular injury was detected by the measurement of ROS levels and MDA, which are important indicators of oxidative damage. Significantly higher levels of ROS and MDA were detected in the CS group compared with those in the HMP group (both P<0.01) (Fig. 3).

Figure 3
Measurement of reactive oxygen species (ROS) and malonaldehyde (MDA) levels in the three groups in order to evaluate the extent of kidney injury. (A) The cold storage (CS) group had significantly increased ROS levels compared with the those in the hypothermic ...

Inflammation of the kidneys decreased in the HMP group compared with that in the CS group

In the basal state, NF-κB is sequestered in the cytoplasm by inhibitory IκB proteins. When IκB kinase β (IKKβ) is activated by pro-inflammatory signaling, it triggers the degradation of IκBα, thereby promoting the nuclear translocation and activation of NF-κB. To verify the degree of inflammation in the kidney, we analyzed the levels of TNF-α by ELISA and RT-qPCR. Furthermore, we evaluated the expression levels of NF-κB and IκBα using western blot analysis and RT-qPCR. The HMP group showed significantly decreased levels of TNF-α and NF-κB compared with those in the CS group (both P<0.01), whereas there was no significant difference in the expression of TNF-α between the HMP and sham group (P>0.05). By contrast, the expression of IκBα in the HMP group was significantly higher than that in the CS group (protein level, P<0.01; mRNA level, P<0.05) (Fig. 4).

Figure 4
Hypothermic machine perfusion (HMP) is associated with less kidney inflammation than cold storage (CS). (A) Nuclear factor-κB (NF-κB) expression was evaluated by western blot analysis. The HMP group showed significantly decreased NF-κB ...

Apoptosis of renal cells significantly decreases in the HMP group compared with that in the CS group

We detected apoptosis of renal cells using TUNEL assay. The rate of apoptosis was approximately 4-fold lower in the HMP group compared with that in the CS group (P<0.01) (Fig. 5), HMP 3.48±0.5%, and CS 13.77±2.0%.

Figure 5
Detection of apoptosis of renal cells by the TdT-mediated biotin-16-dUTP nick-end labeling (TUNEL) assay. The kidney sections were stained with 4′,6-diamidino-2-phenylindole (DAPI) in order to identify the nuclei. The rates of apoptosis in the ...

Expression of ASK1, p-JNK and cleaved caspase-3 significantly decreases in the HMP group compared with that in the CS group

To evaluate whether A20 decreased apoptosis through the ASK1-JNK pathway, the expression of ASK1, JNK and its activated form p-JNK were evaluated by western blot analysis and RT-qPCR (Fig. 6). HMP treatment reduced the activation of ASK1, JNK, specifically reducing the expression of p-JNK compared with that in the CS group (all P<0.01). Compared with the CS group, pro-caspase-3 expression was decreased in the HMP group (P<0.05); furthermore, the expression of its activated form was more significantly decreased in the HMP group (P<0.01). Compared with the sham group, both the HMP and CS groups showed increased expression of p-JNK and cleaved caspase-3 (all P<0.01) (Fig. 6).

Figure 6
Evaluation of the expression of apoptosis signal-regulating kinase 1 (ASK1), c-Jun N-terminal kinase (JNK), phosphorylated (p-)JNK, pro-caspase-3 and cleaved caspase-3 by western blot analysis and RT-qPCR. Representative blots are shown. β-actin ...

RIPK3 expression significantly decreases compared with that in the CS group

RIPK3 expression was evaluated by western blot analysis and RT-qPCR (Fig. 7). RIPK3 expression was significantly lower in the HMP group compared with that in the CS group (P<0.01). Compared with the sham group, both the HMP and CS groups showed increased expression of RIPK3 (both P<0.01). We also measured high mobility group box 1 (HMGB1) release in order to confirm the necrosis of renal cells (38). HMGB1 expression was significantly lower in the HMP group compared with that in the CS group (P<0.01). Both the HMP and CS groups showed increased expression of HMGB1 compared with that in the sham group (both P<0.01).

Figure 7
Receptor-interacting serine-threonine kinase 3 (RIPK3) and high mobility group box 1 (HMGB1) expression significantly decreases in the hypothermic machine perfusion (HMP) group compared with that in the cold storage (CS) group. RIPK3 expression was evaluated ...

Immunohistochemical analysis of paraffin-embedded sections reveals low RIPK3 expression in the HMP group

The expression and location of RIPK3 in the kidney was analyzed by IHC. Only low levels of RIPK3 protein was expressed in the HMP group, whereas significantly higher levels were detected in the CS group (P<0.01). RIPK3 protein was expressed mainly in the TECs (Fig. 8).

Figure 8
Immunohistochemical analysis of the expression and location of RIPK3. Representative images are shown (magnification, ×200). RIPK3 expression was significantly reduced in the hypothermic machine perfusion (HMP) group compared with that in the ...

Discussion

The renal transplant waiting list continues to grow each year, as does the demand for donor organs. To expand the existing pool of organs, the use of kidneys obtained from donors after cardiac death is increasing in most countries. However, there is ongoing controversy regarding the quality of some DCD and ECD grafts compared with standard criteria organs. Such allografts are prone to higher rates of DGF, primary non-function and decreased long-term graft survival (5,39,40). The findings of the multicenter Eurotransplant trial published in 2009 demonstrated that HMP reduced the incidence of DGF (26.5% with CS to 20.8% with HMP) in kidneys obtained from the most common types of deceased donors (8). The three-year follow-up data from this trial also demonstrated improved graft survival with HMP (9). HMP is known to be more appropriate for donor organ storage after cardiac death than CS; however, clarification of the underlying mechanism is urgently required in order to further improve donor organ quality through HMP.

Kidney transplantation is invariably associated with organ damage, including IRI. Following an ischemic episode, the apoptosis and necrosis of TECs occurs initially, and the following EC injury further exacerbates ongoing ischemia of the tubular epithelium as well as the inflammatory response (41,42). TECs are known to be the most susceptible cell type to inflammatory injury, which results in tubular necrosis (43). A previous study has shown the benefit of blocking necroptosis in renal IRI (44). In addition, apoptosis is one of the principal causes of cell death in isolated kidneys and cultured renal tubular cells following IRI (45). Therefore, controlling inflammation and cell death, particularly of TECs, is an attractive therapeutic strategy to reverse acute kidney injury, halt chronic disease and protect renal allografts.

The anti-inflammatory function of A20 is well documented in A20 knockout mice, which are cachectic at birth and die within 3 weeks of birth as a result of uncontrolled inflammation (24). Moreover, TNF-α markedly increases A20 mRNA expression in the kidney (24) and da Silva et al demonstrated that inflammation induces the NF-κB-dependent protein A20 in human renal proximal TECs (RPTECs) (46). These findings are consistent with our results demonstrating that A20 is expressed in rabbit TECs. Hypoxia stimulates NF-κB signaling in epithelial and macrophage cell lines by preventing the repression of IKKβ by oxygen-dependent prolyl hydroxylases (47). In addition, NF-κB may be activated during ischemia/reperfusion (I/R) by changes in the cellular redox potential, which occurs in response to hypoxia (during ischemia) followed by re-oxygenation (during reperfusion) (48). NF-κB transcription factors act as central regulators of inflammation (16). NF-κB is usually sequestered in the cytoplasm in association with inhibitor of NF-κBα, IκBα. Pro-inflammatory signaling leads to IκBα degradation, thereby promoting the nuclear translocation and activation of NF-κB. It is well established that A20, as one of the NF-κB target genes, is involved in a negative feedback loop to block NF-κB activation (24,31). It has been demonstrated that A20 protects vascular ECs, hepatocytes and pancreatic β cells from inflammation (4951). This is consistent with our results showing the potent anti-inflammatory effect of A20 in TECs. In the HMP group, A20 reduced the expression of NF-κB and TNF-α compared with that in the CS group.

A20 was initially characterized as an inhibitor of TNF-induced apoptosis (52). As an anti-apoptotic protein, A20 has been demonstrated to protect breast cancer MCF-7 cells, fibrosarcoma WEHI164 cells, embryonic fibroblast NIH 3T3 cells, ECs and L929 cells from TNF-mediated apoptosis or necrosis (28,5254). A20 acts early in the TNF-α-induced signaling cascade by blocking both TNF-α-induced rapid activation of JNK and processing of the receptor-associated caspase-8 (55). Daniel et al also showed that A20 targets the TNF-α-induced apoptotic pathway by inhibiting the proteolytic cleavage of caspases-8 and -2 as well as caspases-3 and -6 (28). Caspase inhibition using shRNA in order to silence caspase-8 or transgenic overexpression of the endogenous caspase-8 inhibitor c-FLIP has been shown to protect renal TECs against TNF-α-induced apoptosis in vitro and ischemic kidney injury in vivo (56,57). As an alternative mechanism underlying the anti-apoptotic effects of A20, Won et al proposed that A20 binds to ASK1, an important mitogen-activated protein kinase kinase (MAPKK) kinase in the JNK signaling cascade, and mediates ASK1 degradation, leading to the suppression of JNK activation and eventually the inhibition of apoptosis (58). Moreover, A20 may inhibit apoptosis through the suppression of pro-inflammatory cytokines (59). The mitochondria, an organelle found in most cells, are key sites for integrating the death receptor and mitochondrial apoptotic pathway during exogenous stress (60). The caspase family plays an important role in mediating apoptosis. Among them, caspase-3 acts as a key execution molecule that functions in many ways in the transduction of apoptotic signals (61). In the present study, we found that A20 expression in the HMP group was significantly increased compared with that in the CS group. Furthermore, the results of western blot analysis or RT-qPCR revealed that the expression of ASK1, p-JNK and cleaved caspase-3 was significantly reduced compared with that in the CS group. Moreover, TUNEL assay analysis of apoptosis in our study showed that the rate of apoptosis was approximately 4-fold lower in the HMP group compared with that in the CS group. These results are consistent with those of a previous study showing 5-fold lower levels of myocyte apoptosis in the HMP group compared with those in the CS group in an ex vivo rat heart transplantation model (62). In the present study, we demonstrated that A20 is predominantly expressed in the TECs, with significantly more abundant expression in the HMP group compared with that in the CS group. This suggests that HMP decreased the rate of renal cell apoptosis and the subsequent apoptotic cell death pathway during IRI by suppressing the ASK1-JNK signaling cascade.

Generally, necroptosis is defined as cell death mediated through a pathway that depends on the RIPK1-RIPK3 complex that may be inhibited by necrostatin-1 (Nec-1) (63). Necroptosis is induced by a class of death receptors that includes tumor necrosis factor receptor (TNFR)1, TNFR2 and Fas. Among them, the TNF-α/TNFR-induced pathway is the most widely studied. Necroptotic death typically triggers inflammation in vivo due to the release of intracellular molecules from dying cells (19). Necrosis results in the loss of membrane integrity and the release of HMGB1 and other damage-associated molecular patterns (DAMPs) that promote inflammatory responses (64,65). The contribution of RIPK1-dependent necroptosis to kidney failure has also been observed in models of I/R and it may rescued by Nec-1 inhibitor (44). A recently study showed that RIPK1/3 is a regulator of TNF-α-mediated necroptosis in renal TECs and RIPK3-deficient allografts had improved renal function and longer rejection-free survival compared with kidneys from wild-type mice (22). Recently Onizawa et al showed that A20 used its deubiquitinating motif to restrict RIPK3 ubiquitination and the formation of necroptotic RIPK1-RIPK3 complexes and also restricted RIPK3-dependent necroptosis in multiple cell types, although not in renal cells (32). In the present study, RIPK3 protein was expressed mainly in the TECs and in the HMP group, RIPK3 expression was significantly lower than that in the CS group. In addition the HMP group exhibited reduced HMGB1 expression compared with that in the CS group. These results indicate that, compared with CS, HMP induces greater A20 expression during IRI, hence restricting RIPK3-dependent necroptosis and inflammation in TECs.

In the present study, we have demonstrated that A20 may be induced at low temperatures, and that HMP significantly increases A20 expression compared with CS. Thus, we concluded that HMP significantly inhibits inflammation and decreases the apoptosis and necroptosis of renal cells during IRI by inducing the expression of A20. With regard to the mechanism, we suggest that the higher levels of A20 expression in the HMP group are due to the lower levels of MALT1, which cleaves A20 (34), compared with those in the CS group; however the detailed mechanism remains to be fully elucidated and further studies are required to better delineate the molecular targets of A20 in organs stored using the HMP technique.

Acknowledgments

The present study was funded by the National Natural Science Foundation of China (grant no. 81570079).

References

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–1730. doi: 10.1056/NEJM199912023412303. [PubMed] [Cross Ref]
2. Nicholson ML, Metcalfe MS, White SA, Waller JR, Doughman TM, Horsburgh T, Feehally J, Carr SJ, Veitch PS. A comparison of the results of renal transplantation from non-heart-beating, conventional cadaveric, and living donors. Kidney Int. 2000;58:2585–2591. doi: 10.1046/j.1523-1755.2000.00445.x. [PubMed] [Cross Ref]
3. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. 2004;364:1814–1827. doi: 10.1016/S0140-6736(04)17406-0. [PubMed] [Cross Ref]
4. Curci C, Castellano G, Stasi A, Divella C, Loverre A, Gigante M, Simone S, Cariello M, Montinaro V, Lucarelli G, et al. Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrol Dial Transplant. 2014;29:799–808. doi: 10.1093/ndt/gft516. [PubMed] [Cross Ref]
5. Gueler F, Gwinner W, Schwarz A, Haller H. Long-term effects of acute ischemia and reperfusion injury. Kidney Int. 2004;66:523–527. doi: 10.1111/j.1523-1755.2004.761_11.x. [PubMed] [Cross Ref]
6. Kosieradzki M, Rowiński W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc. 2008;40:3279–3288. doi: 10.1016/j.transproceed.2008.10.004. [PubMed] [Cross Ref]
7. St Peter SD, Imber CJ, Friend PJ. Liver and kidney preservation by perfusion. Lancet. 2002;359:604–613. doi: 10.1016/S0140-6736(02)07749-8. [PubMed] [Cross Ref]
8. Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, van Kasterop-Kutz M, van der Heide JJ, Squifflet JP, van Heurn E, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009;360:7–19. doi: 10.1056/NEJMoa0802289. [PubMed] [Cross Ref]
9. Moers C, Pirenne J, Paul A, Ploeg RJ, Machine Preservation Trial Study Group Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2012;366:770–771. doi: 10.1056/NEJMc1111038. [PubMed] [Cross Ref]
10. Zhang Y, Fu Z, Zhong Z, Wang R, Hu L, Xiong Y, Wang Y, Ye Q. Hypothermic machine perfusion decreases renal cell apoptosis during ischemia/reperfusion injury via the Ezrin/AKT pathway. Artif Organs. 2016;40:129–135. doi: 10.1111/aor.12534. [PubMed] [Cross Ref]
11. Schold JD, Kaplan B, Howard RJ, Reed AI, Foley DP, Meier-Kriesche HU. Are we frozen in time? Analysis of the utilization and efficacy of pulsatile perfusion in renal transplantation. Am J Transplant. 2005;5:1681–1688. doi: 10.1111/j.1600-6143.2005.00910.x. [PubMed] [Cross Ref]
12. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12:353–365. doi: 10.1053/j.ackd.2005.07.011. [PubMed] [Cross Ref]
13. Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009;2009:137072. doi: 10.1155/2009/137072. [PMC free article] [PubMed] [Cross Ref]
14. Kono H, Nakagawa K, Morita S, Shinoda K, Mizuno R, Kikuchi E, Miyajima A, Umezawa K, Oya M. Effect of a novel nuclear factor-κB activation inhibitor on renal ischemia-reperfusion injury. Transplantation. 2013;96:863–870. doi: 10.1097/TP.0b013e3182a3df74. [PubMed] [Cross Ref]
15. Latanich CA, Toledo-Pereyra LH. Searching for NF-kappaB-based treatments of ischemia reperfusion injury. J Invest Surg. 2009;22:301–315. doi: 10.1080/08941930903040155. [PubMed] [Cross Ref]
16. Cao CC, Ding XQ, Ou ZL, Liu CF, Li P, Wang L, Zhu CF. In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int. 2004;65:834–845. doi: 10.1111/j.1523-1755.2004.00463.x. [PubMed] [Cross Ref]
17. Hatada EN, Krappmann D, Scheidereit C. NF-kappaB and the innate immune response. Curr Opin Immunol. 2000;12:52–58. doi: 10.1016/S0952-7915(99)00050-3. [PubMed] [Cross Ref]
18. Daemen MA, van't Veer C, Denecker G, Heemskerk VH, Wolfs TG, Clauss M, Vandenabeele P, Buurman WA. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest. 1999;104:541–549. doi: 10.1172/JCI6974. [PMC free article] [PubMed] [Cross Ref]
19. Linkermann A, Green DR. Necroptosis. N Engl J Med. 2014;370:455–465. doi: 10.1056/NEJMra1310050. [PMC free article] [PubMed] [Cross Ref]
20. Kaushal GP, Basnakian AG, Shah SV. Apoptotic pathways in ischemic acute renal failure. Kidney Int. 2004;66:500–506. doi: 10.1111/j.1523-1755.2004.761_6.x. [PubMed] [Cross Ref]
21. Kaushal GP, Kaushal V, Hong X, Shah SV. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int. 2001;60:1726–1736. doi: 10.1046/j.1523-1755.2001.00026.x. [PubMed] [Cross Ref]
22. Lau A, Wang S, Jiang J, Haig A, Pavlosky A, Linkermann A, Zhang ZX, Jevnikar AM. RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am J Transplant. 2013;13:2805–2818. doi: 10.1111/ajt.12447. [PubMed] [Cross Ref]
23. Opipari AW, Jr, Boguski MS, Dixit VM. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem. 1990;265:14705–14708. [PubMed]
24. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 2000;289:2350–2354. doi: 10.1126/science.289.5488.2350. [PMC free article] [PubMed] [Cross Ref]
25. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004;5:1052–1060. doi: 10.1038/ni1110. [PubMed] [Cross Ref]
26. Catrysse L, Vereecke L, Beyaert R, van Loo G. A20 in inflammation and autoimmunity. Trends Immunol. 2014;35:22–31. doi: 10.1016/j.it.2013.10.005. [PubMed] [Cross Ref]
27. Ma A, Malynn BA. A20: Linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol. 2012;12:774–785. doi: 10.1038/nri3313. [PMC free article] [PubMed] [Cross Ref]
28. Daniel S, Arvelo MB, Patel VI, Longo CR, Shrikhande G, Shukri T, Mahiou J, Sun DW, Mottley C, Grey ST, Ferran C. A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. Blood. 2004;104:2376–2384. doi: 10.1182/blood-2003-02-0635. [PubMed] [Cross Ref]
29. Kunter U, Daniel S, Arvelo MB, Choi J, Shukri T, Patel VI, Longo CR, Scali ST, Shrikhande G, Rocha E, et al. Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells. Kidney Int. 2005;68:1520–1532. doi: 10.1111/j.1523-1755.2005.00564.x. [PubMed] [Cross Ref]
30. Grey ST, Longo C, Shukri T, Patel VI, Csizmadia E, Daniel S, Arvelo MB, Tchipashvili V, Ferran C. Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. J Immunol. 2003;170:6250–6256. doi: 10.4049/jimmunol.170.12.6250. [PubMed] [Cross Ref]
31. Coornaert B, Carpentier I, Beyaert R. A20: Central gatekeeper in inflammation and immunity. J Biol Chem. 2009;284:8217–8221. doi: 10.1074/jbc.R800032200. [PMC free article] [PubMed] [Cross Ref]
32. Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, Prodhomme T, Duong B, Whang MI, Advincula R, et al. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol. 2015;16:618–627. doi: 10.1038/ni.3172. [PMC free article] [PubMed] [Cross Ref]
33. Bodonyi-Kovacs G, Strom TB, Putheti P. A20 - a biomarker of allograft outcome: a showcase in kidney transplantation. Adv Exp Med Biol. 2014;809:103–116. doi: 10.1007/978-1-4939-0398-6_7. [PubMed] [Cross Ref]
34. Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol. 2008;9:263–271. doi: 10.1038/ni1561. [PubMed] [Cross Ref]
35. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, Franzoso G. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature. 2001;414:308–313. doi: 10.1038/35104560. [PubMed] [Cross Ref]
36. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A. Inhibition of JNK activation through NF-kappaB target genes. Nature. 2001;414:313–317. doi: 10.1038/35104568. [PubMed] [Cross Ref]
37. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell. 2006;124:601–613. doi: 10.1016/j.cell.2006.01.021. [PubMed] [Cross Ref]
38. Vanden Berghe T, Grootjans S, Goossens V, Dondelinger Y, Krysko DV, Takahashi N, Vandenabeele P. Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods. 2013;61:117–129. doi: 10.1016/j.ymeth.2013.02.011. [PubMed] [Cross Ref]
39. Barba J, Zudaire JJ, Robles JE, Rosell D, Berian JM, Pascual I. Complications of kidney transplantation with grafts from expanded criteria donors. World J Urol. 2013;31:893–900. doi: 10.1007/s00345-012-0831-3. [PubMed] [Cross Ref]
40. McLaren AJ, Jassem W, Gray DW, Fuggle SV, Welsh KI, Morris PJ. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transplant. 1999;13:266–272. doi: 10.1034/j.1399-0012.1999.130308.x. [PubMed] [Cross Ref]
41. Padanilam BJ. Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis. Am J Physiol Renal Physiol. 2003;284:F608–F627. doi: 10.1152/ajprenal.00284.2002. [PubMed] [Cross Ref]
42. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens. 2002;11:301–308. doi: 10.1097/00041552-200205000-00006. [PubMed] [Cross Ref]
43. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int. 2004;66:480–485. doi: 10.1111/j.1523-1755.2004.761_2.x. [PubMed] [Cross Ref]
44. Linkermann A, Bräsen JH, Himmerkus N, Liu S, Huber TB, Kunzendorf U, Krautwald S. Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int. 2012;81:751–761. doi: 10.1038/ki.2011.450. [PubMed] [Cross Ref]
45. Toronyi E. Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008;149:305–315. doi: 10.1556/OH.2008.28212. In Hungarian. [PubMed] [Cross Ref]
46. da Silva CG, Maccariello ER, Wilson SW, Putheti P, Daniel S, Damrauer SM, Peterson CR, Siracuse JJ, Kaczmarek E, Ferran C. Hepatocyte growth factor preferentially activates the anti-inflammatory arm of NF-κB signaling to induce A20 and protect renal proximal tubular epithelial cells from inflammation. J Cell Physiol. 2012;227:1382–1390. doi: 10.1002/jcp.22851. [PMC free article] [PubMed] [Cross Ref]
47. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453:807–811. doi: 10.1038/nature06905. [PMC free article] [PubMed] [Cross Ref]
48. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol. 2002;282:C227–C241. doi: 10.1152/ajpcell.00112.2001. [PubMed] [Cross Ref]
49. Grey ST, Arvelo MB, Hasenkamp W, Bach FH, Ferran C. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. J Exp Med. 1999;190:1135–1146. doi: 10.1084/jem.190.8.1135. [PMC free article] [PubMed] [Cross Ref]
50. Arvelo MB, Cooper JT, Longo C, Daniel S, Grey ST, Mahiou J, Czismadia E, Abu-Jawdeh G, Ferran C. A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology. 2002;35:535–543. doi: 10.1053/jhep.2002.31309. [PubMed] [Cross Ref]
51. Lutz J, Luong A, Strobl M, Deng M, Huang H, Anton M, Zakkar M, Enesa K, Chaudhury H, Haskard DO, et al. The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. J Mol Med Berl. 2008;86:1329–1339. doi: 10.1007/s00109-008-0405-4. [PubMed] [Cross Ref]
52. Opipari AW, Jr, Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem. 1992;267:12424–12427. [PubMed]
53. Hess S, Gottfried E, Smola H, Grunwald U, Schuchmann M, Engelmann H. CD40 induces resistance to TNF-mediated apoptosis in a fibroblast cell line. Eur J Immunol. 1998;28:3594–3604. doi: 10.1002/(SICI)1521-4141(199811)28:11<3594::AID-IMMU3594>3.0.CO;2-D. [PubMed] [Cross Ref]
54. Heyninck K, Denecker G, De Valck D, Fiers W, Beyaert R. Inhibition of tumor necrosis factor-induced necrotic cell death by the zinc finger protein A20. Anticancer Res. 1999;19:2863–2868. [PubMed]
55. Lademann U, Kallunki T, Jäättelä M. A20 zinc finger protein inhibits TNF-induced apoptosis and stress response early in the signaling cascades and independently of binding to TRAF2 or 14-3-3 proteins. Cell Death Differ. 2001;8:265–272. doi: 10.1038/sj.cdd.4400805. [PubMed] [Cross Ref]
56. Du C, Guan Q, Yin Z, Zhong R, Jevnikar AM. IL-2-mediated apoptosis of kidney tubular epithelial cells is regulated by the caspase-8 inhibitor c-FLIP. Kidney Int. 2005;67:1397–1409. doi: 10.1111/j.1523-1755.2005.00217.x. [PubMed] [Cross Ref]
57. Du C, Wang S, Diao H, Guan Q, Zhong R, Jevnikar AM. Increasing resistance of tubular epithelial cells to apoptosis by shRNA therapy ameliorates renal ischemia-reperfusion injury. Am J Transplant. 2006;6:2256–2267. doi: 10.1111/j.1600-6143.2006.01478.x. [PubMed] [Cross Ref]
58. Won M, Park KA, Byun HS, Sohn KC, Kim YR, Jeon J, Hong JH, Park J, Seok JH, Kim JM, et al. Novel anti-apoptotic mechanism of A20 through targeting ASK1 to suppress TNF-induced JNK activation. Cell Death Differ. 2010;17:1830–1841. doi: 10.1038/cdd.2010.47. [PubMed] [Cross Ref]
59. Nagamachi A, Nakata Y, Ueda T, Yamasaki N, Ebihara Y, Tsuji K, Honda Z, Takubo K, Suda T, Oda H, et al. Acquired deficiency of A20 results in rapid apoptosis, systemic inflammation, and abnormal hematopoietic stem cell function. PLoS One. 2014;9:e87425. doi: 10.1371/journal.pone.0087425. [PMC free article] [PubMed] [Cross Ref]
60. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol. 2001;2:67–71. doi: 10.1038/35048073. [PubMed] [Cross Ref]
61. Cho BB, Toledo-Pereyra LH. Caspase-independent programmed cell death following ischemic stroke. J Invest Surg. 2008;21:141–147. doi: 10.1080/08941930802029945. [PubMed] [Cross Ref]
62. Peltz M, He TT, Adams GA, IV, Koshy S, Burgess SC, Chao RY, Meyer DM, Jessen ME. Perfusion preservation maintains myocardial ATP levels and reduces apoptosis in an ex vivo rat heart transplantation model. Surgery. 2005;138:795–805. doi: 10.1016/j.surg.2005.06.040. [PubMed] [Cross Ref]
63. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107–120. doi: 10.1038/cdd.2011.96. [PMC free article] [PubMed] [Cross Ref]
64. Chan FK. Fueling the flames: mammalian programmed necrosis in inflammatory diseases. Cold Spring Harb Perspect Biol. 2012;4:a008805. doi: 10.1101/cshperspect.a008805. [PMC free article] [PubMed] [Cross Ref]
65. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38:209–223. doi: 10.1016/j.immuni.2013.02.003. [PubMed] [Cross Ref]

Articles from International Journal of Molecular Medicine are provided here courtesy of Spandidos Publications